Outcome
    Moderate Evidence

    Alpha Lipoic Acid (ALA) for Antioxidant Protection

    ALA is an unusually versatile antioxidant - both water and fat soluble - and reliably lowers oxidative-stress markers in humans.

    Overview

    Alpha lipoic acid is unusual among antioxidants in being both water and fat soluble, which lets it act in the cytosol, in membranes and in the mitochondrial matrix. Human trials consistently show reductions in oxidative stress markers — malondialdehyde, oxidised LDL and 8-isoprostane — alongside increases in glutathione, typically at 600 mg daily over 8 to 12 weeks. The honest caveat is that biomarker improvement is not the same as clinical benefit.
    Where ALA has clinical endpoints behind it — symptomatic diabetic peripheral neuropathy — the evidence is stronger and the oxidative-stress rationale is best supported. For general antioxidant protection in healthy people, treat the improvement in redox markers as mechanistic evidence, not as a proven health outcome.

    Verdict

    Likely effective

    Randomised trials reliably show improved oxidative stress biomarkers and raised glutathione at 600 mg/day. Translation of those biomarker shifts into clinical outcomes is demonstrated mainly in diabetic neuropathy, not in healthy populations.

    How It Works

    ALA and its reduced form dihydrolipoic acid directly scavenge hydroxyl radicals, hypochlorous acid, singlet oxygen and peroxynitrite. More importantly, dihydrolipoic acid regenerates other antioxidants — vitamin C, vitamin E and coenzyme Q10 — and recycles oxidised glutathione, which is why ALA is often described as a network antioxidant rather than a standalone one.
    It also chelates transition metals such as iron and copper, limiting Fenton-reaction radical generation, and it activates Nrf2 signalling, upregulating the cell's own antioxidant enzymes including glutathione synthesis. This indirect, adaptive route is probably more relevant to sustained protection than direct scavenging. Separately, ALA is an endogenous cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, linking it to mitochondrial energy metabolism as well as redox balance.

    Dosing & Protocol

    Take ALA on an empty stomach — food reduces bioavailability by around 30%. The R-isomer is the biologically active form and is better absorbed than the racemic mixture, so R-lipoic acid can be dosed lower, though most trial data use racemic ALA.

    Evidence

    The relevant evidence is a set of randomised, placebo-controlled trials measuring redox biomarkers in metabolic syndrome, type 2 diabetes and obesity, generally reporting lower malondialdehyde and higher total antioxidant capacity at 600 mg daily. Trials are short, populations are mostly metabolically unwell rather than healthy, and hard outcomes are absent.

    Verdict

    Likely effective

    No individual studies are linked to this pairing yet in our library, so no study list is shown. The verdict rests on the randomised biomarker evidence described above; citations will appear here as they are indexed.

    Safety

    At 600 mg daily ALA is generally well tolerated. Nausea, heartburn and a rash are the usual reports, and become more common at doses above 1200 mg. A distinctive, harmless sulfurous smell to urine is common.

    Blood glucose and thiamine

    ALA improves insulin sensitivity and can cause hypoglycaemia in people taking insulin or sulfonylureas — monitor glucose closely and discuss dose adjustments with your prescriber. Avoid in thiamine deficiency, including heavy alcohol use, until thiamine is replaced. Rare insulin autoimmune syndrome has been reported, predominantly in people of Japanese and Korean descent. Safety in pregnancy and breastfeeding is not established.

    Interactions & Conflicts

    The interactions that matter are metabolic — glucose lowering and metal chelation — rather than hepatic enzyme effects.
    Interacts withSeverityMechanismAction
    major
    		—Monitor blood glucose; medication adjustment via your prescriber
    moderate
    		—Separate by 4 hours; monitor thyroid function
    moderate
    		—Separate by at least 2 hours
    moderate
    		—Only with oncology approval
    major
    		—Replace thiamine first

    References

    References

    No individual trials are currently linked to this pairing in our study library. The verdict is based on randomised trials of alpha lipoic acid and oxidative stress biomarkers; linked citations will be listed here as they are indexed.

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.